TCL Archive FDA examining endpoints for approval of cancer therapies, potential departure from survival as the gold standard, Oncology Division Director Richard Pazdur says in interview. November 7, 2003
TCL Archive ‘We Cannot Tolerate One Third Reduction In Centers. Prevention, Clinical Trials Programs’ September 20, 1991